STAYVEER

This brand name is authorized in Austria, Croatia, Cyprus, Estonia, Finland, Ireland, Lithuania, Poland, Spain, UK.

Active ingredients

The drug STAYVEER contains one active pharmaceutical ingredient (API):

1
UNII Q326023R30 - BOSENTAN
 

Bosentan is a dual endothelin receptor antagonist (ERA) with affinity for both endothelin A and B (ETA and ETB) receptors. Bosentan decreases both pulmonary and systemic vascular resistance resulting in increased cardiac output without increasing heart rate.
 
Read more about Bosentan

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group Classification
C02KX01 Bosentan C Cardiovascular system → C02 Antihypertensives → C02K Other antihypertensives → C02KX Antihypertensives for pulmonary arterial hypertension
Discover more medicines within C02KX01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
EE Ravimiamet 1619300, 1619311, 1674288, 1674299
ES Centro de información online de medicamentos de la AEMPS 113832001, 113832002
FI Lääkealan turvallisuus- ja kehittämiskeskus 171072, 383002
GB Medicines & Healthcare Products Regulatory Agency 348896
LT Valstybinė vaistų kontrolės tarnyba 1070753, 1070754, 1076188, 1076189, 1081756, 1081757
PL Rejestru Produktów Leczniczych 100316125, 100316131

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈